Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS: JUNE ISSUE PUBLISHED
  • JUNE 2021 Issue has been successfully launched on 1 June 2021.

Abstract

BIOEQUIVALENCE STUDY OF TWO ORAL LINCOMYCIN-SPECTINOMYCIN COMBINATIONS (LINCO-SPECTIN 100® AND RIGHTO-SPECTIN® IN BROILER CHICKENS

Ashraf Elkomy and Mohamed Aboubakr*

ABSTRACT

The present study was designed to assess the comparative bio-equivalence of Linco-Spectin 100® and Righto-spectin® in healthy broiler chickens after oral administration of both products in a dose of 16.65 mg lincomycin hydrochloride and 33.35 mg spectinomycin sulphate/kg b.wt. Twenty four broiler chickens were divided into two groups. The first group was designed to study the pharmacokinetics of Linco-Spectin 100®, while the 2nd group was designed to study the pharmacokinetics of Righto-spectin®. Each broiler chicken in both groups was orally administered with 16.65 mg lincomycin and 33.35 mg spectinomycin /kg b.wt. Blood samples were obtained from the wing vein and collected immediately before and at 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours after a single oral administration. The disposition kinetics of Linco-Spectin 100® and Righto-spectin® following oral administration of 16.65 mg lincomycin and 33.35 mg spectinomycin /kg b.wt, revealed that the maximum blood concentration of lincomycin [Cmax] were 4.81 and 4.62 μg/ml and attained at [tmax] of 1.36 and 1.35 hours, respectively. Spectinomycin in both products could not be detected in blood after oral administration that make this antibiotic of choice for treatment of enteric infections caused by organisms sensitive to spectinomycin. In conclusion: Righto-spectin® is bioequivalent to Linco-Spectin 100® since the ratios of Cmax, AUC0-24 and AUC0-∞ (T/R) was 0.96, 0.92 and 0.91 respectively. These are within the bioequivalence acceptance range. Righto-spectin® and Linco-Spectin 100® are therefore bioequivalent and interchangeable.

Keywords: .


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More